Search

Your search keyword '"Tamura, Kenji"' showing total 2,071 results
Start Over Author "Tamura, Kenji"
2,071 results on '"Tamura, Kenji"'

2. A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

Author

Noguchi, Emi, Yamanaka, Takashi, Mukai, Hirofumi, Yamamoto, Naohito, Chung, Chi-Feng, Lu, Yen-Shen, Chang, Dwan-Ying, Sohn, Joohyuk, Kim, Gun Min, Lee, Kyung-Hun, Lee, Soo-Chin, Iwasa, Tsutomu, Iwata, Hiroji, Watanabe, Kenichi, Jung, Kyung Hae, Tanabe, Yuko, Kang, Seok Yun, Yasojima, Hiroyuki, Aogi, Kenjiro, Tokunaga, Eriko, Sim, Sung Hoon, Yap, Yoon Sim, Matsumoto, Koji, Tseng, Ling-Ming, Umeyama, Yoshiko, Sudo, Kazuki, Kojima, Yuki, Hata, Tomomi, Kuchiba, Aya, Shibata, Taro, Nakamura, Kenichi, Fujiwara, Yasuhiro, Tamura, Kenji, and Yonemori, Kan

Published
2024
Full Text
View/download PDF

4. Calibration and performance of the readout system based on switched capacitor arrays for the Large-Sized Telescope of the Cherenkov Telescope Array

Author

Nozaki, Seiya, Awai, Kyosuke, Bamba, Aya, Barrio, Juan Abel, Bernardos, Maria Isabel, Blanch, Oscar, Boix, Joan, Cassol, Franca, Choushi, Yuki, Delgado, Carlos, Diaz, Carlos, Fouque, Nadia, Freixas, Lluis, Gliwny, Pawel, Gunji, Shunichi, Hadasch, Daniela, Hoffmann, Dirk, Houles, Julien, Inome, Yusuke, Iwamura, Yuki, Jouvin, Léa, Katagiri, Hideaki, Kawamura, Kiomei, Kerszberg, Daniel, Konno, Yusuke, Kubo, Hidetoshi, Kushida, Junko, Kobayashi, Yukiho, López-Coto, Rubén, Martinez, Gustavo, Masuda, Shu, Mazin, Daniel, Moralejo, Abelardo, Moretti, Elena, Nagayoshi, Tsutomu, Nakamori, Takeshi, Nishijima, Kyoshi, Nogami, Yuto, Nogués, Leyre, Ohoka, Hideyuki, Oka, Tomohiko, Okazaki, Nao, Okumura, Akira, Orito, Reiko, Panazol, Jean-Luc, Paoletti, Riccardo, Pio, Cristobal, Polo, Miguel, Prast, Julie, Saito, Takayuki, Sakurai, Shunsuke, Sitarek, Julian, Sunada, Yuji, Suzuki, Megumi, Takahashi, Mitsunari, Tamura, Kenji, Tanaka, Manobu, Tejedor, Luis Angel, Terada, Yukikatsu, Teshima, Masahiro, Tsukamoto, Yusuke, and Yamamoto, Tokonatsu

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

The Cherenkov Telescope Array (CTA) is the next-generation ground-based very-high-energy gamma-ray observatory. The Large-Sized Telescope (LST) of CTA is designed to detect gamma rays between 20 GeV and a few TeV with a 23-meter diameter mirror. We have developed the focal plane camera of the first LST, which has 1855 photomultiplier tubes (PMTs) and the readout system which samples a PMT waveform at GHz with switched capacitor arrays, Domino Ring Sampler ver4 (DRS4). To measure the precise pulse charge and arrival time of Cherenkov signals, we developed a method to calibrate the output voltage of DRS4 and the sampling time interval, as well as an analysis method to correct the spike noise of DRS4. Since the first LST was inaugurated in 2018, we have performed the commissioning tests and calibrated the camera. We characterised the camera in terms of the charge pedestal under various conditions of the night sky background, the charge resolution of each pixel, the charge uniformity of the whole camera, and the time resolutions with a test pulse and calibration laser., Comment: 14 pages, 13 figures, Proceedings of the SPIE Astronomical Telescopes + Instrumentation, 114470H (2020)

Published
2022
Full Text
View/download PDF

12. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study

Author

Schmid, Peter, Lipatov, Oleg, Im, Seock-Ah, Goncalves, Anthony, Muñoz-Couselo, Eva, Lee, Keun Seok, Tamura, Kenji, Testa, Laura, Witzel, Isabell, Ohtani, Shoichiro, Turner, Nicholas, Zambelli, Stefania, Harbeck, Nadia, Andre, Fabrice, Dent, Rebecca, Mejia, Jaime A., Zhou, Xuan, Haiderali, Amin, Nguyen, Allison Martin, Cortes, Javier, and Winer, Eric P.

Published
2023
Full Text
View/download PDF

13. Therapeutic target biomarkers of patient-derived xenograft models of gastric-type cervical adenocarcinoma

Author

Kojima, Yuki, Yoshida, Hiroshi, Okuya, Toshihiro, Okuma, Hitomi S, Nishikawa, Tadaaki, Tanioka, Maki, Sudo, Kazuki, Noguchi, Emi, Shimoi, Tatsunori, Tamura, Kenji, Tanase, Yasuhito, Uno, Masaya, Ishikawa, Mitsuya, Arakaki, Motoko, Ichikawa, Hitoshi, Yagishita, Shigehiro, Hamada, Akinobu, Fujiwara, Yasuhiro, Yonemori, Kan, and Kato, Tomoyasu

Published
2023
Full Text
View/download PDF

14. Systematic comparison of Mg K-edge XANES spectra of magnesium-bearing clay minerals and magnesium silicate hydrates: A promising tool for identifying magnesium silicate hydrate in natural samples

Author

Inoue, Kosuke, Nishiki, Yuto, Fukushi, Keisuke, Suma, Reo, Sato, Tsutomu, Sakuma, Hiroshi, Tamura, Kenji, Yokoyama, Shingo, Shimbashi, Misato, Mizukami, Tomoyuki, Unami, Kensuke, Noji, Yohei, Kitajima, Takuma, Fukaya, So, Takeichi, Yasuo, Yamashita, Shohei, Suga, Hiroki, and Takahashi, Yoshio

Published
2023
Full Text
View/download PDF

16. Prognosis and effectiveness of chemotherapy for medullary breast carcinoma

Author

Aihara, Tomohiko, Kumamaru, Hiraku, Ishitobi, Makoto, Miyashita, Minoru, Miyata, Hiroaki, Tamura, Kenji, Yoshida, Masayuki, Ogo, Etsuyo, Nagahashi, Masayuki, Asaga, Sota, Kojima, Yasuyuki, Kadoya, Takayuki, Aogi, Kenjiro, Niikura, Naoki, Iijima, Kotaro, Hayashi, Naoki, Kubo, Makoto, Yamamoto, Yutaka, Takeuchi, Yoshinori, Imoto, Shigeru, and Jinno, Hiromitsu

Published
2022
Full Text
View/download PDF

17. Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan

Author

Shimomura, Akihiko, Nagahashi, Masayuki, Kumamaru, Hiraku, Aogi, Kenjiro, Asaga, Sota, Hayashi, Naoki, Iijima, Kotaro, Kadoya, Takayuki, Kojima, Yasuyuki, Kubo, Makoto, Miyashita, Minoru, Miyata, Hiroaki, Niikura, Naoki, Ogo, Etsuyo, Tamura, Kenji, Tanakura, Kenta, Yoshida, Masayuki, Yamamoto, Yutaka, Imoto, Shigeru, and Jinno, Hiromitsu

Published
2022
Full Text
View/download PDF

20. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Author

Modi, Shanu, Saura, Cristina, Yamashita, Toshinari, Park, Yeon Hee, Kim, Sung-Bae, Tamura, Kenji, Andre, Fabrice, Iwata, Hiroji, Ito, Yoshinori, Tsurutani, Junji, Sohn, Joohyuk, Denduluri, Neelima, Perrin, Christophe, Aogi, Kenjiro, Tokunaga, Eriko, Im, Seock-Ah, Lee, Keun Seok, Hurvitz, Sara A, Cortes, Javier, Lee, Caleb, Chen, Shuquan, Zhang, Lin, Shahidi, Javad, Yver, Antoine, and Krop, Ian

Subjects
Cancer, Clinical Research, Breast Cancer, Clinical Trials and Supportive Activities, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Camptothecin, Consolidation Chemotherapy, Female, Humans, Immunoconjugates, Intention to Treat Analysis, Kaplan-Meier Estimate, Lung Diseases, Interstitial, Middle Aged, Progression-Free Survival, Receptor, ErbB-2, Trastuzumab, DESTINY-Breast01 Investigators, Receptor, erbB-2, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundTrastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 dose-finding study, a majority of the patients with advanced HER2-positive breast cancer had a response to trastuzumab deruxtecan (median response duration, 20.7 months). The efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine requires confirmation.MethodsIn this two-part, open-label, single-group, multicenter, phase 2 study, we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2-positive metastatic breast cancer who had received previous treatment with trastuzumab emtansine. In the first part of the study, we evaluated three different doses of trastuzumab deruxtecan to establish a recommended dose; in the second part, we evaluated the efficacy and safety of the recommended dose. The primary end point was the objective response, according to independent central review. Key secondary end points were the disease-control rate, clinical-benefit rate, duration of response and progression-free survival, and safety.ResultsOverall, 184 patients who had undergone a median of six previous treatments received the recommended dose of trastuzumab deruxtecan (5.4 mg per kilogram of body weight). In the intention-to-treat analysis, a response to therapy was reported in 112 patients (60.9%; 95% confidence interval [CI], 53.4 to 68.0). The median duration of follow-up was 11.1 months (range, 0.7 to 19.9). The median response duration was 14.8 months (95% CI, 13.8 to 16.9), and the median duration of progression-free survival was 16.4 months (95% CI, 12.7 to not reached). During the study, the most common adverse events of grade 3 or higher were a decreased neutrophil count (in 20.7% of the patients), anemia (in 8.7%), and nausea (in 7.6%). On independent adjudication, the trial drug was associated with interstitial lung disease in 13.6% of the patients (grade 1 or 2, 10.9%; grade 3 or 4, 0.5%; and grade 5, 2.2%).ConclusionsTrastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppression, interstitial lung disease was observed in a subgroup of patients and requires attention to pulmonary symptoms and careful monitoring. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.).

Published
2020

21. Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry

Author

Terada, Mitsuo, Miyashita, Minoru, Kumamaru, Hiraku, Miyata, Hiroaki, Tamura, Kenji, Yoshida, Masayuki, Ogo, Etsuyo, Nagahashi, Masayuki, Asaga, Sota, Kojima, Yasuyuki, Kadoya, Takayuki, Aogi, Kenjiro, Niikura, Naoki, Iijima, Kotaro, Hayashi, Naoki, Kubo, Makoto, Yamamoto, Yutaka, and Jinno, Hiromitsu

Published
2022
Full Text
View/download PDF

24. Soil-Forming Factors

Author

Tamura, Kenji, Miura, Hideki, Kaneko, Shinji, Sano, Tetsuya, Kubotera, Hideo, Hartemink, Alfred E., Series Editor, Hatano, Ryusuke, editor, Shinjo, Hitoshi, editor, and Takata, Yusuke, editor

Published
2021
Full Text
View/download PDF

25. Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan

Author

Yotsumoto, Daisuke, Sagara, Yasuaki, Kumamaru, Hiraku, Niikura, Naoki, Miyata, Hiroaki, Kanbayashi, Chizuko, Tsuda, Hitoshi, Yamamoto, Yutaka, Aogi, Kenjiro, Kubo, Makoto, Tamura, Kenji, Hayashi, Naoki, Miyashita, Minoru, Kadoya, Takayuki, Saji, Shigehira, Toi, Masakazu, Imoto, Shigeru, and Jinno, Hiromitsu

Published
2022
Full Text
View/download PDF

27. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

Author

Friedlander, Michael, Gebski, Val, Gibbs, Emma, Davies, Lucy, Bloomfield, Ralph, Hilpert, Felix, Wenzel, Lari B, Eek, Daniel, Rodrigues, Manuel, Clamp, Andrew, Penson, Richard T, Provencher, Diane, Korach, Jacob, Huzarski, Tomasz, Vidal, Laura, Salutari, Vanda, Scott, Clare, Nicoletto, Maria Ornella, Tamura, Kenji, Espinoza, David, Joly, Florence, and Pujade-Lauraine, Eric

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 5.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Good Health and Well Being, Adult, Aged, Antineoplastic Agents, BRCA1 Protein, BRCA2 Protein, Carcinoma, Ovarian Epithelial, Female, Humans, Maintenance Chemotherapy, Middle Aged, Mutation, Neoplasm Recurrence, Local, Phthalazines, Piperazines, Progression-Free Survival, Quality of Life, Surveys and Questionnaires, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundIn the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who had received two or more lines of previous chemotherapy. The most common subjective adverse effects included fatigue, nausea, and vomiting, which were typically low grade and self-limiting. Our a-priori hypothesis was that maintenance olaparib would not negatively affect health-related quality of life (HRQOL) and additionally that the prolongation of progression-free survival with olaparib would be underpinned by additional patient-centred benefits.MethodsIn SOLO2, 196 patients were randomly assigned to olaparib tablets (300 mg twice daily) and 99 to placebo. Randomisation was stratified by response to previous chemotherapy (complete vs partial) and length of platinum-free interval (>6-12 vs >12 months). The prespecified primary HRQOL analysis evaluated the change from baseline in the Trial Outcome Index (TOI) score during the first 12 months of the study. To be assessable, patients had to have an evaluable score at baseline and at least one evaluable follow-up form. Secondary planned quality-of-life (QOL) analyses included the duration of good quality of life (defined as time without significant symptoms of toxicity [TWiST] and quality-adjusted progression-free survival [QAPFS]). Efficacy and QOL outcomes were analysed in all randomly assigned patients (the full analysis set), and safety outcomes were analysed in all randomly assigned patients who received at least one dose of study drug. This ongoing study is registered with ClinicalTrials.gov, number NCT01874353, and is closed to new participants.FindingsThe adjusted average mean change from baseline over the first 12 months in TOI was -2·90 (95% CI -4·13 to -1·67) with olaparib and -2·87 (-4·64 to -1·10) with placebo (estimated difference -0·03; 95% CI -2·19 to 2·13; p=0·98). Mean QAPFS (13·96 [SD 10·96] vs 7·28 [5·22] months; difference 6·68, 95% CI 4·98-8·54) and mean duration of TWiST (15·03 [SD 12·79] vs 7·70 [6·42] months; difference 7·33, 95% CI 4·70-8·96) were significantly longer with olaparib than with placebo.InterpretationOlaparib maintenance therapy did not have a significant detrimental effect on HRQOL compared with placebo. There were clinically meaningful patient-centred benefits in both TWiST and QAPFS despite the adverse effects associated with olaparib. These patient-centred endpoints support the improvement in progression-free survival, the primary endpoint in SOLO2, and should be included in future trials of maintenance therapies.FundingAstraZeneca.

Published
2018

28. Contribution of tumour and immune cells to PD‐L1 expression as a predictive biomarker in metastatic triple‐negative breast cancer: exploratory analysis from KEYNOTE‐119

Author

Cortes, Javier, primary, Winer, Eric P, additional, Lipatov, Oleg, additional, Im, Seock‐Ah, additional, Gonçalves, Anthony, additional, Muñoz‐Couselo, Eva, additional, Lee, Keun Seok, additional, Schmid, Peter, additional, Tamura, Kenji, additional, Testa, Laura, additional, Witzel, Isabell, additional, Ohtani, Shoichiro, additional, Hund, Stephanie, additional, Kulangara, Karina, additional, Karantza, Vassiliki, additional, Mejia, Jaime A, additional, Ma, Junshui, additional, Jelinic, Petar, additional, Huang, Lingkang, additional, Pruitt, Scott K, additional, and Emancipator, Kenneth, additional

Published
2024
Full Text
View/download PDF

33. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Author

Korach, Jacob, Huzarski, Tomasz, Byrski, Tomasz, Pautier, Patricia, Friedlander, Michael, Harter, Philipp, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Nicoletto, Maria, Nussey, Fiona, Clamp, Andrew, Penson, Richard, Oza, Amit, Poveda Velasco, Andrés, Rodrigues, Manuel, Lotz, Jean-Pierre, Selle, Frédéric, Ray-Coquard, Isabelle, Provencher, Diane, Prat Aparicio, Aleix, Vidal Boixader, Laura, Scott, Clare, Tamura, Kenji, Yunokawa, Mayu, Lisyanskaya, Alla, Medioni, Jacques, Pécuchet, Nicolas, Dubot, Coraline, De La Motte Rouge, Thibault, Kaminsky, Marie-Christine, Weber, Béatrice, Lortholary, Alain, Parkinson, Christine, Ledermann, Jonathan, Williams, Sarah, Banerjee, Susana, Cosin, Jonathan, Hoffman, James, Plante, Marie, Covens, Allan, Sonke, Gabe, Joly, Florence, Floquet, Anne, Hirte, Holger, Amit, Amnon, Park-Simon, Tjoung-Won, Matsumoto, Koji, Tjulandin, Sergei, Hoon Kim, Jae, Gladieff, Laurence, Sabbatini, Roberto, O'Malley, David, Timmins, Patrick, Kredentser, Daniel, Laínez Milagro, Nuria, Barretina Ginesta, Maria Pilar, Tibau Martorell, Ariadna, Gómez De Liaño Lista, Alfonso, Ojeda González, Belén, Mileshkin, Linda, Mandai, Masaki, Boere, Ingrid, Ottevanger, Petronella, Nam, Joo-Hyun, Filho, Elias, Hamizi, Salima, Cognetti, Francesco, Warshal, David, Dickson-Michelson, Elizabeth, Kamelle, Scott, McKenzie, Nathalie, Rodriguez, Gustavo, Armstrong, Deborah, Chalas, Eva, Celano, Paul, Behbakht, Kian, Davidson, Susan, Welch, Stephen, Helpman, Limor, Fishman, Ami, Bruchim, Ilan, Sikorska, Magdalena, Słowińska, Anna, Rogowski, Wojciech, Bidziński, Mariusz, Śpiewankiewicz, Beata, Casado Herraez, Antonio, Mendiola Fernández, César, Gropp-Meier, Martina, Saito, Toshiaki, Takehara, Kazuhiro, Enomoto, Takayuki, Watari, Hidemichi, Choi, Chel Hun, Kim, Byoung-Gie, Weon Kim, Jae, Hegg, Roberto, Vergote, Ignace, Poveda, Andrés, Ledermann, Jonathan A, Asher, Rebecca, Penson, Richard T, Oza, Amit M, Baldoni, Alessandra, Sonke, Gabe S, Kim, Jae-Hoon, Filho, Elias Abdo, Milenkova, Tsveta, Lowe, Elizabeth S, Rowe, Phil, and Pujade-Lauraine, Eric

Published
2021
Full Text
View/download PDF

34. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Author

Winer, Eric P, Lipatov, Oleg, Im, Seock-Ah, Goncalves, Anthony, Muñoz-Couselo, Eva, Lee, Keun Seok, Schmid, Peter, Tamura, Kenji, Testa, Laura, Witzel, Isabell, Ohtani, Shoichiro, Turner, Nicholas, Zambelli, Stefania, Harbeck, Nadia, Andre, Fabrice, Dent, Rebecca, Zhou, Xuan, Karantza, Vassiliki, Mejia, Jaime, and Cortes, Javier

Published
2021
Full Text
View/download PDF

41. Comparison of perioperative and oncological outcomes between extracorporeal and intracorporeal urinary diversion following laparoscopic radical cystectomy and robot-assisted radical cystectomy

Author

Fukuhara, Hideo, primary, Osakabe, Hiroto, additional, Nao, Tomoya, additional, Shimamoto, Tsutomu, additional, Fukada, Satoshi, additional, Tamura, Kenji, additional, Ashide, Shingo, additional, Karashima, Takashi, additional, and Inoue, Keiji, additional

Published
2023
Full Text
View/download PDF

49. Annual report of the Japanese Breast Cancer Registry for 2017

Author

Hayashi, Naoki, Kumamaru, Hiraku, Isozumi, Urara, Aogi, Kenjiro, Asaga, Sota, Iijima, Kotaro, Kadoya, Takayuki, Kojima, Yasuyuki, Kubo, Makoto, Miyashita, Minoru, Miyata, Hiroaki, Nagahashi, Masayuki, Niikura, Naoki, Ogo, Etsuyo, Tamura, Kenji, Tanakura, Kenta, Yamamoto, Yutaka, Yoshida, Masayuki, Imoto, Shigeru, and Jinno, Hiromitsu

Published
2020
Full Text
View/download PDF

50. Annual report of the Japanese Breast Cancer Society registry for 2016

Author

Kubo, Makoto, Kumamaru, Hiraku, Isozumi, Urara, Miyashita, Minoru, Nagahashi, Masayuki, Kadoya, Takayuki, Kojima, Yasuyuki, Aogi, Kenjiro, Hayashi, Naoki, Tamura, Kenji, Asaga, Sota, Niikura, Naoki, Ogo, Etsuyo, Iijima, Kotaro, Tanakura, Kenta, Yoshida, Masayuki, Miyata, Hiroaki, Yamamoto, Yutaka, Imoto, Shigeru, and Jinno, Hiromitsu

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results